63 results about "Myc-tag" patented technology

The invention is related to a recombinant single-chain tri-specific antibody made from anti-Tumor Associated Antigen (TAA) antibody, FC interlinker, anti-CD3 antibody, HSA interlinker and anti-CD28 antibody in turn. Particularly, the invention relates to an anti-CEA, anti-CD3, anti-CD28 recombinant single-chain tri-specific antibody, CEA-scTsAb, which was constructed with three tandem antibody fragments (anti-CEA scFv, anti-CD3 scFv and anti-CD28 single-domain antibody) linked by two interlinkers (FC interlinker, HSA interlinker), and could be appended by C myc tag or histidine tag ((His)₆-tag) at the C terminal. It also concerns a method for construction, expression and purification of the antibody. It also offers the encoded DNA sequence of the antibody, expression vectors and host cells for the vectors.

The invention discloses an indirect ELISA detection kit of sheep echinococciosis Eg95 protein antibody. The invention is characterized in that the kit comprises an echinococcus granulosus recombinantantigen Eg95 protein precoated ELISA plate, a serum diluent, an enzyme-labeled conjugate diluent, a positive control solution, a negative control solution, an enzyme-labeled conjugate, a washing solution, a substrate developing solution and a stopping solution. During the preparation process of the echinococcus granulosus recombinant antigen, a His tag sequence and a Myc tag sequence are respectively connected to the front and back of the Eg95 gene; then, EcoR I and Xho I are adopted for simultaneous digestion of a PCR product and an eukaryotic expression vector pPIC9K, the target fragment andthe vector are connected after gel extraction, recombinant plasmid pPIC9K-(His-Eg95-Myc) is constructed, the recombinant plasmid is transformed into pichia pastoris GS115 strain, and the recombinantantigen Eg95 is expressed by the induction of methanol and purified by the use of Ni-NTA. The sheep echinococciosis antibody detection kit obtained by the adoption of the dual-tag sequence and eukaryotic expression vector system has strong specificity, high sensitivity and good repeatability, and is easy to operate.

The invention discloses a Pichia pastoris transformant capable of expressing human recombinant interleukin-3 (rhIL-3) with high efficiency and a purification method thereof. In the method, the eukaryotic host is pichia pastorisX-33. The purification method comprises the following steps: cloning a human IL-3 gene; establishing a eukaryotic expression vector, and transforming the eukaryotic expression vector into the eukaryotic yeast host; obtaining a yeast transformant for high-level secretory expression by screening, wherein the IL-3 expressed by the yeasts are available in a glycosylated mode and a non-glycosylated module; and performing amplified culture by using a shake flask, and subjecting the supernate of the culture solution to dialysis, nickel affinity purification and further purification by diethylaminoethanol (DEAE) anion column. The purified product is subjected to mass spectrometric identification and analysis, and the result of the mass spectometric identification and analysis indicates that the expressed IL-3 is modified by different glycosyls and that the IL-3 has an his*6 tag and a C-MYC tag and is easy for purification and detection of expression product. In the invention, different from the conventional method using a prokaryotic host to express the rhIL-3, the method for expressing a large amount of rhIL-3 by using a Pichia pastoris expression system is adopted for the first time, quick purification is realized by using a His-tag protein, the purified rhIL-3 is high-activity rhIL-3 protein which is glycosylated to different extents and of which the molecular weight is 19kDa and 22kDa. The method ensures that the high-activity rhIL-3 recombinant protein is obtained quickly.

The invention discloses a manufacturing method and application of an insect in-vitro protein interaction detecting system. At the positions of amino acid residues at the 159th bit and the 160th bit, mCherry is divided into a segment NmC and a segment CmC through a PCR method, and then the segment NmC and the segment CmC are each fused with a connecting zone sequence, a c-Myc label and a poly(A) sequence to form four fused segments; the four fused segments are each connected with a pIE-MCS plasmid with an autographa californica multiple nuclear polyhedrosis virus ie1 gene promoter and a gp64 gene poly(A) sequence to establish expression plasmids; the expression plasmids are combined to form an insect cell dimolecular fluorescent complementary detecting system. The method is simple and easy to implement, and the established dimolecular fluorescent complementary detecting system expands the application of an insect cell expression system and provides a convenient and effective technological means for insect proteomics and research on protein interaction between insects and pathogenic microorganisms of the insects.

This application discloses a non-radiolabeled immunoprecipitation method for detecting inflammatory myopathy-specific autoantibody MDA5. The present invention provides the following method: constructing a plasmid containing the MDA5 C-terminus (447‑1025aa) and the N-terminus with a Myc tag HEK293 cells were transiently transfected with pCMV‑myc‑MDA5C, and serum from patients with inflammatory myopathy was immunoprecipitated with HEK293 cell lysates overexpressing the MDA5 C-terminus, followed by SDS‑PAGE gel electrophoresis and detection with c‑myc antibody Precipitated MDA5C-terminus solves the problem that there are no commercial ELISA kits for detecting MDA5 antibodies and western blot strips in China, as well as the high cost, high false positive rate and radiolabeling of ELISA kits that self-coat MDA5 antigens The safety of immunoprecipitation and other issues.

The invention discloses a recombinant human interleukin (IL) 15 long peptide fragment and a production method thereof. The production method comprises the following steps: obtaining a human IL-15 long peptide fragment gene; establishing an eukaryotic expression vector and transforming the vector into Pichia pastoris X-33; performing resistance screening on high-level secretory-expressed yeast transformants; performing induced expression, purifying the supernate through a nickel column and an ion exchange column to obtain rhIL-15L. The production method is characterized in that the amino acid residue Ala of the site Kex2P1' of the vector pPICZAlphaA is mutated into Pro and the Pichia pastoris X-33 is taken as host bacteria, and therefore, mass high-efficiency stable expression of the rhIL-15L is realized; the recombinant protein rhIL-15L produced by the method is marked with HIS and C-MYC tags and prone to protein purification and detection; besides, the recombinant protein rhIL-15L is a glycoprotein which is modified through glycosylation to a certain extent, and therefore, the recombinant protein rhIL-15L has excellent bioactivity and is capable of effectively maintaining the proliferation and the bioactivity of human NK (Natural killer) cells in vitro and of a mouse in vivo.

The invention discloses a method for preparing and identifying double-labeled virus-like particles (VLPs) of PRRSV, and relates to the field of biological research technology; a pMD18T recombinant plasmid containing GP5, M and N protein coding genes ORF5, ORF6 and ORF7 is prepared as an amplification template, a Myc tag is introduced at the end of the ORF5, a His tag is introduced into the end ofthe ORF6, a recombinant plasmid is obtained by recombination to PpH and Pp10 promoters of a binary vector, the recombinant plasmid is transferred into DH10Bac E. coli to obtain a recombinant bacmid; and the ORF7 and a pFastBacHTB vector are recombined to obtain a recombinant bacmid. The two recombinant bacmids are inoculated into SF9 cells, and Myc-GP5, His-M and His-N proteins are successfully expressed and automatically assembled into the VLPs. The method lays a foundation for studying the function of the GP5 and M and N major structural proteins and developing VLP vaccines that can distinguish between infection and immunity.

The invention provides an affinity adsorption material based on a c-Myc label nano antibody, belongs to the field of genetic engineering and particularly provides a c-Myc label-oriented single-domain heavy-chain antibody (also known as a nano antibody). The affinity adsorption material has an amino acid sequence shown as SEQ ID NO.1. The amino acid sequence can serve as a precursor, a mutant having better properties (affinity, specificity, stability and the like) can be obtained by improving with a random or site-specific mutagenesis technology, the nano antibody having the high specificity can serve as the c-Myc-oriented immuno-affinity adsorption material, and the recombinant protein containing c-Myc label is purified.

The invention discloses recombination human HM-TRALL protein with an amino acid sequence shown in the SEQ ID NO.1. The method comprises the steps that a human recombination HM-TRALL protein expression carrier containing a His6-Myc label is built at first, recombination bacteria for expressing human recombination HM-TRALL protein are built through the carrier, recombinant expression is carried out on the recombination human HM-TRALL protein through IPTG induction, extraction and purification are carried out, and high-purity HM-TRAIL protein is obtained. The recombination human HM-TRALL protein can selectively induce apoptosis of breast cancer cells in vitro, and will not cause normal breast cell apoptosis. The prepared recombination human HM-TRALL protein has the advantages of being good in stability and high in dissolving degree, can obviously induce apoptosis of tumor cells and is good in application prospect.

The invention belongs to the field of genetic engineering and particularly provides a single-domain heavy chain antibody targeted at c-Myc labels. The antibody has an amino acid sequence shown in SEQ ID NO.:1 and can be used in fields such as immunodetection, antigen enrichment and purification and the like. The amino acid sequence can serve as a precursor and be improved with a random or site-specific mutagenesis technique, so that a mutant with better properties including compatibility, specificity, stability and the like can be obtained and used for developing protein or polypeptides for medicine, industry and agriculture.

The invention belongs to the field of genetic engineering and particularly provides a single-domain and heavy-chain antibody specific to a c-Myc tag. The single-domain and heavy-chain antibody has an amino acid sequence represented as SEQ ID NO.:1 and can be applied to fields of immunodetection, antigen enrichment and purification and the like. Theamino acid sequence can be taken as a precursor and is modified with a random or site-directed mutagenesis technology, so that mutants with better properties such as affinity, specificity, stability and the like can be obtained and are used for developing protein or polypeptides for medicine, industry and agriculture.

The invention belongs to the field of gene engineering, and in particular discloses a single-domain heavy-chain antibody (also known as nano-antibody) aiming at a c-Myc label, and the antibody has an amino acid sequence as shown in SEQ ID NO. 1. The amino acid sequence provided by the invention can be used as a precursor, and by conducting reconstruction through a random or fixed-point mutation technique, a mutant with better properties (affinity, specificity, stability and the like) can be obtained. The nano-antibody with high specificity can be used as an immunoaffinity adsorbing material aiming at c-Myc and used for purifying recombinant protein containing the c-Myc label.

The invention discloses a method for efficiently expressing foreign protein. The method comprises the steps of cloning a foreign protein gene onto a pMYC2 carrier, enabling the foreign protein gene and an encoding genes of six MYC tags on the pMYC2 carrier to form a fused gene, and then utilizing an agrobacterium infection transformation method to express the foreign protein in tobacco leaves instantly and efficiently; utilizing affinity media carried with corresponding tag antibodies to efficiently purify the protein expressed by tobacco according to MYC affinity tags carried by recombinant protein and finally performing competitive elution of the affinity media to obtain purified target protein. The purified protein can be used for further biological function research. The method achieves protein purification in one step and is simple and quick, and the protein purity is high. The foreign recombinant protein can be used for biological safety evaluation and biological function research.

This invention relates to a fusion protein of chenotactic peptide and bispecific antibody against ovarian carcinoma and CD3 molecules. The fusion protein is constructed by sequentially connecting N-terminated 18-peptides of secondary lymphoid tissue chemokine, (GGGGS)2 linking peptide, and the bispecific antibody against ovarian carcinoma and CD3 molecules. C-myc label and His6 label are connected at the C-terminal. This invention also relates to the method for constructing, expressing and purifying the fusion protein, its coding sequence, its relevant expression vector, and the host cells containing the expression vector.

The invention discloses a safe and efficient TCR gene targeted to CD19. The TCR gene is characterized in that a nucleotide sequence of the TCR gene is SEQ ID NO.1, and the TCR gene is formed by CD8leader, CD19scFv, TRBC, T2A, CD8leader, myc-tag and TRAC which are sequentially connected in series. The invention also discloses a preparation method of the TCR gene, a plasmid with the TCR gene, a kitand an application. The TCR gene disclosed by the invention has the advantages that clinical effectiveness and safety of a TCR technology are improved, and fussy experimental operations are also avoided.

The invention belongs to the field of gene engineering, and in particular discloses a single-domain heavy-chain antibody (also known as nano-antibody) aiming at a c-Myc label, and the antibody has an amino acid sequence as shown in SEQ ID NO. 1. The amino acid sequence provided by the invention can be used as a precursor, and by conducting reconstruction through a random or fixed-point mutation technique, a mutant with better properties (affinity, specificity, stability and the like) can be obtained. The nano-antibody with high specificity can be used as an immunoaffinity adsorbing material aiming at c-Myc and used for purifying recombinant protein containing the c-Myc label.

There are provided peptide tags derived from bacteriophytochrome (BphP) that is photoreceptor protein of Deinococcusradiodurans, an antibody capable of specifically recognizing the peptide tags, hybridoma cell lines capable of producing the antibody, and uses thereof. The novel peptide tag has advantages in that it has a short length and can remove a non-specific reaction of the conventional c-myc tag and FLAG tag. Therefore, in the case of using the novel peptide tag and antibody thereto, the fusion protein expressed in a recombinant cell can be very effectively detected or purified. In addition, an epitope tagging system including the novel peptide tag and antibody thereto can be applied in various fields such as a determination of an intracellular site, a confirmation of functionality, detection and purification of specific protein, and researches on interaction between proteins.

The invention belongs to the field of gene engineering and particularly provides a single-domain heavy-chain antibody aiming to a c-Myc tag. The amino acid sequence of the antibody is represented as the SEQ ID No.1. The antibody can be used in the fields of immunodetection, enrichment and purification of antigens, etc. The amino acid sequence, as a precursor, can be modified through random or site-directed mutation technology, so that a mutant having better properties (e.g. affinity, specificity and stability) can be produced and can be further applied to proteins or polypeptides in the fields of medicines, industry and agriculture.

The invention provides a preparation method of an MYC tag fusion expression vector, which comprises the following steps: using a KpnI/XhoI double-enzyme digestion pGL3 Basic vector to obtain a recovered product of the KpnI/XhoI double-enzyme digestion pGL3 Basic vector, using a pRGEB32Bar-Cas9 plasmid as a template to obtain a 2 * 35S promoter PCR recovered product, carrying out a ligation reaction to obtain an intermediate vector pGL-35S, carrying out double-enzyme digestion, connecting an MCS annealing primer to obtain an intermediate vector pGL-35S-MCS, carrying out double-enzyme digestion, connecting a Nos Ter sequence, carrying out double-enzyme digestion, and carrying out purification to obtain the MYC tag fusion expression vector. The MYC tag fusion expression vector is characterized in that an intermediate vector pGL-35S-MCS-Nos is obtained by using an MYC tag as a template, the intermediate vector pGL-35S-MCS-Nos is connected with a connecting peptide Linker primer subjected to denaturation annealing after double enzyme digestion to obtain an intermediate vector pGL-35S-MCS-Linker-Nos, and the intermediate vector pGL-35S-MCS-Linker-Nos is connected with an MYC tag annealing primer after double enzyme digestion to obtain the MYC tag The MYC tag fusion expression vector prepared by the invention has a small framework, has a full length of 4052bp, and is suitable for plant protoplast transformation.

The invention of the application discloses a nonradioactive labeling immunoprecipitation method for detecting an NXP2 autoantibody of inflammatory myopathies and application. A plasma pCMV-myc-NXP2N or pCMV-myc-NXP2C which comprises an NXP2 N end (1-500aa) or an NXP2 C end (400-939aa) and has a Myc tag is constructed, an HEK293 cell is transiently transfected, a serum of an inflammatory myopathies patient with positive NXP2 autoantibody is subjected to immunoprecipitation with an HEK293 cell lysis buffer with an overexpressed NXP2 N end or an NXP2 C end, the NXP2 N end or the NXP2 C end is found to be precipitated by the NXP2 autoantibody, the to-be-detected serum of the inflammatory myopathies patient is subjected to immunoprecipitation with the HEK293 cell lysis buffer with the overexpressed NXP2 C end, then SDS-PAGE gel electrophoresis is implemented, and the precipitated NXP2 C end is detected by a c-myc antibody to determine whether the NXP2 autoantibody exists in the serum of the inflammatory myopathies patient. The problem that no immunoblotting membrane strip or ELISA (Enzyme-Linked Immuno Sorbent Assay) kit for commercially detecting the NXP2 autoantibody exists in the domestic at present is solved, and the problems of high cost of the ELISA kit autonomously coating an NXP2 antigen, high false positive rate, safety of a radioactive labeling immunoprecipitation method and the like are solved.

The invention belongs to the field of genetic engineering and discloses a single-domain heavy chain antibody aiming at a c-Myc label. The single-domain heavy chain antibody is named as a nano-antibody and has an amino acid sequence shown in the formula of SEQ ID NO. 1. Through a random or site-directed mutagenesis technique, a mutant has better properties (such as affinity, specificity and stability) is obtained based on the amino acid sequence as a precursor. The high-specificity nanometer antibody can be used as an immuno-affinity absorption material aiming at c-Myc for purification of a c-Myc label-containing recombinant protein.

The invention belongs to the field of genetic engineering and in particular relates to a single domain heavy chain antibody (also known as a nano antibody) specific to a c-Myc label, and the single domain heavy chain antibody has an amino acid sequence shown in SEQ ID NO.1. The amino acid sequence provided by the invention can be taken as a precursor, modification is carried out by virtue of a random or site-directed mutagenesis technology, a mutant with better properties (affinity, specificity, stability and the like) can be obtained, and the high-specificity nano antibody can serve as an immunoaffinity adsorption material specific to c-Myc and purify recombinant proteins containing the c-Myc label.